Advertisement

Synthesis and Biochemical Evaluation of 5-Tethered Boron-Containing Pyrimidine Nucleosides for BNCT

  • Feng-Guang Rong
  • Albert H. Soloway
  • Seiichiro Ikeda
  • David H. Ives

Abstract

In order for BNCT to be successful, a major need is the development of boron compounds, which penetrate the blood-brain barrier (BBB), target tumor cells selectively, and maintain a relatively high concentration of boron-10 in the tumor, ca. 30 ug/g of tumor tissue, vis-à-vis surrounding normal tissues. Boron-containing nucleosides that use a carrier-mediated transport process for penetrating the CNS and have the potential for becoming incorporated into proliferating cells may be useful agents for BNCT.1 This fact led to the attempts to synthesize carborane-containing nucleoside derivatives. Yamamoto2 and Schinazi3 have attached the carborane moiety to the 5-position on the pyrimidine nucleosides, either directly or through a bulky substituent. Unfortunately, these compounds are very poor substrates for nucleoside kinases, and are unlikely to demontrate the requisite biological activity. This may be due to the fact that having a bulky substituent, like the carborane moiety, attached directly on the 5-position may inhibit enzymatic conversion of the 5-carboranyl-2′-deoxyuridine to their corresponding nucleotides. The formation of the latter is a necessary precondition for the incorporation of such nucleotides into DNA.

Keywords

Thymidine Kinase Bulky Substituent Boron Compound Pyrimidine Nucleoside Amine Hydrochloride 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    I. M. Wyzlic, W. Tjarks, A. H. Soloway, A. K. M. Anisuzzaman, F.-G. Rong and R. F. Barth, Strategies for the design and synthesis of boronated nucleic acid and protein components as potential delivery agents for neutron capture therapy, Int. J. Radiation Oncology Biol. Phys., 28: 1203–1213, 1994.CrossRefGoogle Scholar
  2. 2.
    Y. Yamamoto, T. Seko, F.-G. Rong and H. Nemoto, A new synthetic method via condensation with aldehydes having boronic moiety,Tetra. Lett., 30: 7191–7194, 1989.Google Scholar
  3. 3.
    R. F. Schinazi, N. M. Goudgaon, G. Fulcrand, Y. El Kattan, Z. Lesnikowski, G. Ullas, J. Moravek and D. C. Liotta, Cellular pharmacology and biological activity of 5-carboranyl-2’-deoxyuridine, Int. J. Radiation Oncology Biol. Phys., 28: 1113–1114, 1994.CrossRefGoogle Scholar
  4. 4.
    C. R. Lowe and P. D. G. Dean, Spacer molecules and steric considerations, in “Affinity Chromatography”, Wiley-Interscience, John Wiley & Sons: London, 1974, pp 23–32.Google Scholar
  5. 5.
    F.-G. Rong and A. H. Soloway, Synthesis of 5-tethered carborane-containing pyrimidine nucleosides as potential agents for DNA incorporation, Nucleosides & Nucleotides, 13: 2021–2034, 1994.CrossRefGoogle Scholar
  6. 6.
    L.-S. Lee and Y.-C. Cheng, Human deoxythymidine kinase II: substrate specificity and kinetic behavior of the cytoplasmic and mitochondria) isozymes derived from blast cells of acute myelocytic leukemia, Biochem., 15: 3686–3690, 1976.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Feng-Guang Rong
    • 1
  • Albert H. Soloway
    • 1
  • Seiichiro Ikeda
    • 2
  • David H. Ives
    • 2
  1. 1.College of PharmacyThe Ohio State UniversityColumbusUSA
  2. 2.College of Biological SciencesThe Ohio State UniversityColumbusUSA

Personalised recommendations